Advanced Search

Show simple item record

dc.contributor.authorYılmaz, İlhan
dc.contributor.authorErdoğan, Uzay
dc.contributor.authorTanrıverdi, Osman
dc.contributor.authorGünaldı, Ömür
dc.contributor.authorAdilay, Hüseyin Utku
dc.contributor.authorÖmeroğlu, Muhammed
dc.contributor.authorTanık, Canan
dc.contributor.authorTuğcu, Bekir
dc.date.accessioned2019-08-16T11:40:18Z
dc.date.available2019-08-16T11:40:18Z
dc.date.issued2018en_US
dc.identifier.issn1019-5149
dc.identifier.urihttps://doi.org/10.5137/1019-5149.JTN.22633-18.2
dc.identifier.urihttps://hdl.handle.net/20.500.12462/6020
dc.descriptionAdilay, Hüseyin Utku (Balikesir Author)en_US
dc.description.abstractAIM: To evaluate bevacizumab for epidural fibrosis (EF) treatment in an experimental rat model using histopathology as well as immunohistochemical staining for CD105 and osteopontin (OPN). MATERIAL and METHODS: Sixteen Wistar Albino rats underwent either laminectomy alone to induce EF (group I, control) or laminectomy plus local bevacizumab treatment (group II). The degree of EF was compared between groups using the current histopathological grading method as well as immunohistochemistry for CD105 and OPN. In addition, the consistency of EF staging using CD105 and OPN expression was compared to that using histopathology. RESULTS: The grade of EF was significantly lower in group II than in group I based on the fibroblast count and fibrosis density determined using histopathology, as well as by CD105 expression determined using immunohistochemistry. In contrast, OPN expression was not a reliable marker for EF evaluation because it did not show a significant difference between the two groups. CONCLUSION: Bevacizumab prevents EF development as assessed using both histopathology and CD105 expression. CD105 is a potentially reliable marker for the immunohistochemical grading of EF, in contrast to OPN.en_US
dc.description.sponsorshipTurkish Neurosurgical Societyen_US
dc.language.isoengen_US
dc.publisherTurkish Neurosurgical Societyen_US
dc.relation.isversionof10.5137/1019-5149.JTN.22633-18.2en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBevacizumaben_US
dc.subjectCD105en_US
dc.subjectEpidural Fibrosisen_US
dc.subjectOsteopontinen_US
dc.subjectVEGFen_US
dc.titleEvaluation of bevacizumab for the treatment of epidural fibrosis by immunohistochemical staining for CD105 and osteopontinen_US
dc.typearticleen_US
dc.relation.journalTurkish Neurosurgeryen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0003-4867-244Xen_US
dc.identifier.volume28en_US
dc.identifier.issue6en_US
dc.identifier.startpage954en_US
dc.identifier.endpage962en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record